Search | Clinical Trials Finder

Conditions: Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer, Bladder Cancer
Interventions: Trastuzumab, Pertuzumab, Erlotinib, Vemurafenib, Cobimetinib, Vismodegib, Alectinib, Atezolizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 60
States / cities: Goodyear, Arizona • Phoenix, Arizona • Springdale, Arkansas + 47 more

Conditions: Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Alectinib, Brigatinib, Carboplatin, Ceritinib, Cisplatin, Crizotinib, Ensartinib, Lorlatinib, Pemetrexed; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 491
States / cities: Goodyear, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 341 more

Conditions: ALK-positive Non-small Cell Lung Cancer (NSCLC), RET-positive Non-small Cell Lung Cancer (NSCLC), RET-positive Thyroid Cancer
Interventions: Alectinib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 4
States / cities: Irvine, California • Boston, Massachusetts

Conditions: Non-Small Cell Lung Cancer
Interventions: Alectinib, Atezolizumab, Erlotinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 10
States / cities: Orange, California • New Haven, Connecticut • Orlando, Florida + 5 more

Conditions: Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
Interventions: Neladalkib (NVL-655), Alectinib; Drug
Lead sponsor: Nuvalent Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 23
States / cities: Glendale, Arizona • Newport Beach, California • Orange, California + 19 more

Conditions: Non-Small-Cell Lung Carcinoma
Interventions: Erlotinib, Alectinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 17
States / cities: Birmingham, Alabama • Fullerton, California • Orange, California + 14 more

Conditions: Non-small Cell Lung Cancer
Interventions: Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Pralsetinib, Atezolizumab, SBRT, Resection, Chemotherapy, Divarasib; Drug · Procedure
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 38
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 28 more

Conditions: ALK-positive Advanced NSCLC
Interventions: Brigatinib; Drug
Lead sponsor: Ariad Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 10
States / cities: Orange, California • Whittier, California • Pueblo, Colorado + 7 more

Conditions: Healthy Volunteer
Interventions: Alectinib, Esomeprazole, High Fat and Calorie Meal, Standard Meal; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: Neladalkib (NVL-655), Midazolam, Repaglinide, Itraconazole; Drug
Lead sponsor: Nuvalent Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 21
States / cities: Orange, California • Sacramento, California • Stanford, California + 16 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Osimertinib, Savolitinib, Gefitinib, Necitumumab, Durvalumab, Carboplatin, Pemetrexed, Alectinib, Selpercatinib, Selumetinib, Etoposide, Cisplatin, Datopotamab deruxtecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 16
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 11 more

Conditions: Anaplastic Lymphoma Kinase, Anaplastic Large Cell Lymphoma
Interventions: Alectinib, Duvelisib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Cancer
Interventions: Atezolizumab, Bevacizumab, Alectinib, Cobimetinib, Vemurafenib, FAP IL2V, Venetoclax, Enzalutamide, Pembrolizumab, Sunitinib, Niraparib, Cabozantinib, Pemetrexed, Paclitaxel, Emactuzumab, Rucaparib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 7
States / cities: Aurora, Colorado • Trumbull, Connecticut • Boston, Massachusetts + 3 more

Conditions: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Alectinib, Bevacizumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-Small-Cell Lung Carcinoma
Interventions: Alectinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: ALK+ Advanced NSCLC
Interventions: Brigatinib, Alectinib; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 4
States / cities: Whittier, California • Athens, Georgia • Albany, New York + 1 more

Conditions: Non-Small Cell Lung Cancer
Interventions: brigatinib; Drug
Lead sponsor: Criterium, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 4
States / cities: Denver, Colorado • Durham, North Carolina • Nashville, Tennessee + 1 more

Conditions: ALK Fusion-positive Solid or CNS Tumors
Interventions: Alectinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Up to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 7
States / cities: Palo Alto, California • St. Petersburg, Florida • Ann Arbor, Michigan + 4 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Alectinib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 45
States / cities: Bimingham, Alabama • Daphne, Alabama • Mobile, Alabama + 35 more

Conditions: ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Interventions: ALECENSA - alectinib hydrochloride capsule; Drug
Lead sponsor: Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair; Industry
Eligibility: 24 Years to 64 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Doral, Florida • Rockville, Maryland

Conditions: Solid Tumors
Interventions: Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab emtansine, Inavolisib, Belvarafenib, Pralsetinib, Divarasib, Camonsertib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Not listed
Enrollment: 920 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 32
States / cities: Goodyear, Arizona • Los Angeles, California • Newport Beach, California + 25 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Alectnib, Cisplatin, Vinorelbine, Gemcitabine, Pemetrexed, Carboplatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 3
States / cities: Chicago, Illinois • Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Anaplastic Lymphoma Kinase-positive, Carcinoma Non-small-cell Lung
Interventions: Brigatinib, Alectinib, Ceritinib, Lorlatinib, Any FDA Approved ALK Inhibitors; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Maynard, Massachusetts

Conditions: Non-Small Cell Lung Cancer
Interventions: Alectinib, Entrectinib, Durvalumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 2
States / cities: Tigard, Oregon • Pittsburgh, Pennsylvania

Search by objective public record fields.

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns

A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)